Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS

Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS

Source: 
BioSpace
snippet: 

The FDA on Tuesday gave Servier’s Tibsovo (ivosidenib tablets) an additional indication, allowing its use in patients with relapsed or refractory myelodysplastic syndromes carrying a susceptible IDH1 mutation.